menu
    • menu

    Company profile for Kymab

    Sanofi-PSE
    News
    Sanofi's $1.1B eczema drug hits goal, spurring talk of phase 3

    28 Jun 2023

    // Nick Paul Taylor FIERCE BIOTECH

    Incyte pens $885M AI pact to use Genesis' GEMS to develop drugs

    21 Feb 2025

    // FIERCE BIOTECH

    AstraZeneca boosts China presence with FibroGen's anemia drug in $160M deal

    21 Feb 2025

    // REUTERS

    DATA COMPILATION
    #PharmaFlow

    Sanofi

    Contact Supplier

    Website

    Biotech Digital Meet

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Based in Cambridge, UK, we are a clinical-stage biopharmaceutical company developing a deep pipeline of novel human antibody-based therapies in a broad range of indications. Our unique platforms generate a vast repertoire of fully-human, species cross-reactive and affinity-matured antibodies against challenging targets.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kymabunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    The Bennet Building (B930) Babraham Research Campus Cambridge CB22 3AT
    Telephone
    Telephone
    +44 (0)1223 833301
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.kymab.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kymab-ltd/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/KymabLtd
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's $1.1B eczema drug hits goal, spurring talk of phase 3
    Sanofi's $1.1B eczema drug hits goal, spurring talk of phase 3

    28 Jun 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sanofis-11b-eczema-drug-hits-midphase-goal-spurring-talk-phase-3-and-new-indications

    Nick Paul Taylor FIERCE BIOTECH
    28 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search